Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is employed to treat acute attacks of hereditary angioedema in affected individuals.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Icatibant Fresenius is used to manage hereditary angioedema by blocking the bradykinin pathway.

Hereditary angioedema (HAE) attacks: provides rapid relief of swelling and associated pain. HAE type I: reduces the severity and duration of acute episodes. HAE type II: mitigates bradykinin‑mediated vascular permeability during attacks.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Swelling: transient edema at the site of administration. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: transient light‑headed sensation.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: unexpected swelling of the face, lips, or airway. - Severe hypotension: marked drop in blood pressure. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count. - Severe allergic reaction: systemic hypersensitivity requiring discontinuation.

When prescribing Icatibant Fresenius, clinicians should consider several safety precautions.

Pregnancy: consult a healthcare provider; safety not established. Breastfeeding: caution advised; excretion in milk is unknown. Renal impairment: monitor patients; no specific dosage adjustment known. Concomitant ACE inhibitors: may increase risk of angioedema. Hypersensitivity: discontinue if a severe allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: increased risk of angioedema. - Angiotensin receptor blockers: may potentiate bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely): - Diuretics: possible additive blood‑pressure effects. - Other bradykinin‑modulating agents: additive risk of swelling. - NSAIDs: may heighten hypersensitivity reactions.